February 26, 2025 02:02 PM ESTUpdated 02:42 PM
FDA+

Af­ter re­jec­tion, Re­gen­eron seeks ac­cel­er­at­ed ap­proval of bis­pe­cif­ic for on­ly one of two types of lym­phoma

Lei Lei Wu

News Reporter

Re­gen­eron is now ex­pect­ing an ac­cel­er­at­ed ap­proval de­ci­sion this sum­mer on its T cell en­gager for one form of lym­phoma, while it’s giv­ing up on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Re­gen­eron, two Chi­nese biotechs tout promise of their hear­ing loss gene ther­a­pies

Eikon Ther­a­peu­tics rais­es $351M Se­ries D as lead drug starts Phase 3

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times